Novartis AG (NOVN) - Financial and Strategic SWOT Analysis Review

Novartis AG (NOVN) - Financial and Strategic SWOT Analysis Review


- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Novartis AG (Novartis) is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, hematologic diseases, solid tumors, immune disorders, and infections, among others. Novartis conducts research in various disease areas through the BioMedical Research division. The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.

Novartis AG Key Recent Developments

Apr 23,2024: Novartis Delivers Double-Digit Sales Growth and Core Margin Expansion in Q1, Fy 2024 Guidance Raised
Apr 12,2024: Novartis signs deal for Arvinas’ prostate cancer therapy
Mar 15,2024: Novartis Expands Its Biopharmaceutical Manufacturing Site in Singapore
Mar 14,2024: Biotech's Role in Addressing the Pancreatic Cancer Emergency

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note:Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
Novartis AG - Key Facts
Novartis AG - Key Employees
Novartis AG - Key Employee Biographies
Novartis AG - Major Products and Services
Novartis AG - History
Novartis AG - Company Statement
Novartis AG - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
Section 2 – Company Analysis
Company Overview
Novartis AG - Business Description
Geographical Segment: Asia/Africa/Australasia
Performance
Geographical Segment: Canada and Latin America
Performance
Geographical Segment: Europe
Performance
Geographical Segment: US
Performance
R&D Overview
Novartis AG - Corporate Strategy
Novartis AG - SWOT Analysis
SWOT Analysis - Overview
Novartis AG - Strengths
Novartis AG - Weaknesses
Novartis AG - Opportunities
Novartis AG - Threats
Novartis AG - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Novartis AG, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
Novartis AG, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
Novartis AG, Recent Deals Summary
Section 5 – Company’s Recent Developments
Apr 23, 2024: Novartis Delivers Double-Digit Sales Growth and Core Margin Expansion in Q1, Fy 2024 Guidance Raised
Apr 12, 2024: Novartis signs deal for Arvinas’ prostate cancer therapy
Mar 15, 2024: Novartis Expands Its Biopharmaceutical Manufacturing Site in Singapore
Mar 14, 2024: Biotech's Role in Addressing the Pancreatic Cancer Emergency
Mar 05, 2024: Novartis Shareholders Approve All Resolutions Proposed by the Board of Directors at the Annual General Meeting
Jan 31, 2024: Novartis Delivers Strong Full Year Performance, 10% Net Sales and 18% Core Operating Income Growth (Cc¹), With Margin Expansion. Continuing Innovation Momentum With Multiple Positive Ph3 Readouts
Jan 31, 2024: Care Access Becomes Newest Member of the National Lipid Association Industry Council, Joining Novartis, Amgen, and Other Cardiovascular Health Leaders
Jan 17, 2024: Envision Energy Announces Collaboration with Five Global Healthcare Leaders to Unlock Renewable Energy in Davos
Nov 30, 2023: Atropos Health Forms Life Science Advisory Board, Increasing Commitment to Accelerated Drug Development and Clinical Trial Diversity and Inclusion
Nov 28, 2023: Novartis Upgrades Mid-Term Sales Growth Guidance, Showcases Its Differentiated Innovative Medicines Strategy and Robust Pipeline at R&D Day
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
Novartis AG, Key Facts
Novartis AG, Key Employees
Novartis AG, Key Employee Biographies
Novartis AG, Major Products and Services
Novartis AG, History
Novartis AG, Subsidiaries
Novartis AG, Joint Venture
Novartis AG, Key Competitors
Novartis AG, Ratios based on current share price
Novartis AG, Annual Ratios
Novartis AG, Annual Ratios (Cont...1)
Novartis AG, Annual Ratios (Cont...2)
Novartis AG, Interim Ratios
Novartis AG, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
Novartis AG, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
Novartis AG, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Novartis AG, Performance Chart (2019 - 2023)
Novartis AG, Ratio Charts
Novartis AG, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
Novartis AG, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings